The vimentin-targeting monoclonal antibody hzVSF-V13 reduces TH17 cell numbers and osteoclastogenesis to attenuate rheumatoid arthritis progression
Immunology Letters · 2026
DOI: 10.1016/j.imlet.2026.107189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Letters, 2026. Verfasst von A Ram Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic Universit…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Vimentin, Osteoclasts, Th17 Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea, Grains Research and Development Corporation.
Abstract (Originalsprache)
BACKGROUND: In an inflammatory environment, damage to vimentin (Vim) can induce its citrullination. Together with the formation of immune complexes, citrullinated Vim further stimulates inflammatory processes, leading to chronic inflammation. Patients with rheumatoid arthritis (RA), an autoimmune disease, have elevated levels of anti-citrullinated Vim antibodies. METHODS: Therefore, we aimed to demonstrate the effects of a Vim-targeting IgG4 monoclonal antibody in RA. hzVSF-V13 treatment reduced arthritis severity and induced immunoregulatory effects, as indicated by a reduction in Th17 cells and pro-inflammatory cytokines. RESULTS: Decrease in citrullinated Vim-specific IgG levels in serum were accompanied by a decrease in citrullinated Vim in joint tissue. Also, it reduced the expression of osteoclast differentiation factors in RA patient samples. CONCLUSIONS: These results suggest the ability of hzVSF-V13 to suppress inflammation and osteoclast differentiation not only in an animal model of collagen-induced arthritis, but also in RA patients. The clinical application of hzVSF-V13 may lead to effective treatment of RA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Pathology, College…
- Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of…
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Grains Research and Development Corporation
Zitieren
APA
Lee, A. R., Choi, H., Lee, S. Y., Choi, J. W., Han, S. G., & Cho, M. L. (2026). The vimentin-targeting monoclonal antibody hzVSF-V13 reduces TH17 cell numbers and osteoclastogenesis to attenuate rheumatoid arthritis progression. Immunology Letters. https://doi.org/10.1016/j.imlet.2026.107189
Vancouver
Lee AR, Choi H, Lee SY, Choi JW, Han SG, Cho ML. The vimentin-targeting monoclonal antibody hzVSF-V13 reduces TH17 cell numbers and osteoclastogenesis to attenuate rheumatoid arthritis progression. Immunology Letters. 2026. doi:10.1016/j.imlet.2026.107189
BibTeX
@article{Lee2026,
author = {Lee, A Ram and Choi, Haeyoun and Lee, Seon-Yeong and Choi, Jeong Won and Han, Se Gyeong and Cho, Mi-La},
title = {The vimentin-targeting monoclonal antibody hzVSF-V13 reduces TH17 cell numbers and osteoclastogenesis to attenuate rheumatoid arthritis progression},
journal = {Immunology Letters},
year = {2026},
doi = {10.1016/j.imlet.2026.107189}
}
EUVIMED